- Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
- Berger BT, Labriola MK, Antonarakis ES, Armstrong AJ.
- BMJ Case Rep. 2023 Jan 18;16(1):e251320. doi: 10.1136/bcr-2022-251320.
- PMID: 36653039
- PubMed abstract
- Source abstract
- Case report
- Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
- Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, Jia L, Chen HD, Bao XB, Guo N, Huan XJ, Xi Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Chen Y, Ding J, Lang JY, Miao ZH, Zhang A, He JX.
- EMBO Mol Med. 2023 Jan 18:e16235. doi: 10.15252/emmm.202216235. Epub ahead of print.
- PMID: 36652375
- PubMed abstract
- Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
- Gerald T, Margulis V, Meng X, Bagrodia A, Cole S, Qin Q, Call SG, Mauer E, Lotan Y, Woldu SL.
- Urol Oncol. 2023 Jan 16:S1078-1439(22)00493-8. doi: 10.1016/j.urolonc.2022.12.008. Epub ahead of print.
- PMID: 36653279
- PubMed abstract
- Source abstract
- Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
- Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, Lin Y, Liu Z, Cao Y, Zhang G, Shang S, Zhang Y, Wang K.
- JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337.
- PMID: 36652665
- PubMed abstract
- Source abstract
•• Identifier: NCT03154749: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 18.)